Limited Offer
Mast Cell Disorders, An Issue of Immunology and Allergy Clinics of North America
- 1st Edition, Volume 43-4 - September 28, 2023
- Editor: Cem Akin
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 1 8 1 8 3 - 2
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 8 1 8 4 - 9
In this issue of Immunology & Allergy Clinics, guest editor Dr. Cem Akin brings his considerable expertise to the topic of Mast Cell Disorders. Top experts in the field provide… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quote-
Contains 9 relevant, practice-oriented topics including drug and venom allergy in mastocytosis; quality of life in mastocytosis; effect of gender and special considerations for women in mastocytosis and anaphylaxis; management of mediator symptoms, allergy, and anaphylaxis in mastocytosis; and more.
-
Provides in-depth clinical reviews on mast cell disorders, offering actionable insights for clinical practice.
-
Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Forthcoming Issues
- Foreword
- Preface
- World Health Organization Classification and Diagnosis of Mastocytosis: Update 2023 and Future Perspectives
- Key points
- Introduction and historical background
- Review and discussion of the current classification of MC disorders
- Updated WHO classification of mastocytosis 2022
- Cutaneous mastocytosis versus skin involvement in SM
- Major and minor criteria to diagnose SM: update 2023
- Diagnostic criteria for bone marrow mastocytosis (BMM) and separation from other SM variants
- Updated formulation of B-findings and C-findings
- Updated criteria of smoldering systemic mastocytosis
- Refined criteria for ASM and ASM variants
- SM-AHN and AHN variants: status 2023
- Refinements in the diagnosis of MCL and mast cell sarcoma (MCS)
- Diagnostic criteria and classification of MCAS and related conditions
- Global classification of mast cell disorders
- Summary
- Clinics care points
- Authors’ contributions
- Conflicts of interest
- Funding
- KIT Mutations and Other Genetic Defects in Mastocytosis: Implications for Disease Pathology and Targeted Therapies
- Key points
- Introduction
- Diagnostic criteria and classification of mastocytosis
- The role of KIT mutations in the pathophysiology of mastocytosis
- The role of non-KIT mutations in the pathophysiology and prognosis of different systemic mastocytosis variants
- Methods to detect (and quantify) KIT mutations in mastocytosis
- Quantification of the KIT D816V mutational burden for prognostication and monitoring of therapeutic efficacy
- Concluding remarks and open questions
- Clinics care points
- Disclosure
- Pediatric and Hereditary Mastocytosis
- Key points
- Introduction
- Summary
- Clinics care points
- Funding
- Management of Mediator Symptoms, Allergy, and Anaphylaxis in Mastocytosis
- Key points
- Introduction
- General features of allergy and anaphylaxis
- Mastocytosis
- Symptoms of mediator release and anaphylaxis in mastocytosis
- Mast cell activation syndromes
- Management of mediator-related symptoms in mastocytosis
- Summary
- Clinics care points
- Funding
- Disclosure
- Drug and Venom Allergy in Mastocytosis
- Key points
- Introduction
- Venom hypersensitivity
- Nonsteroidal antiinflammatory drugs
- Radiocontrast media
- Opioids
- Perioperative anaphylaxis
- Antibiotics
- Vaccines
- Drug allergy in children and pregnant women
- Summary
- Clinics care points
- Disclosure
- Gastrointestinal Disease in Mastocytosis
- Key points
- Introduction
- Background
- Gastrointestinal manifestations of indolent systemic mastocytosis
- Discussion, including controversies
- Summary
- Clinics care points
- Conflict of interest
- Management of Advanced Systemic Mastocytosis and Associated Myeloid Neoplasms
- Key points
- Introduction
- Pathophysiology, clinical features, and diagnosis of advanced systemic mastocytosis
- Management of advanced systemic mastocytosis
- Prognostic markers in advanced systemic mastocytosis
- Conclusion and future perspectives
- Disclosure
- Clinics care points
- Tyrosine Kinase Inhibitors in Non-advanced Systemic Mastocytosis
- Key points
- Introduction
- Tyrosine kinase inhibitors in non-advanced systemic mastocytosis
- Summary and future perspectives
- Clinics care points
- Conflict of interest statement
- Measuring Symptom Severity and Quality of Life in Mastocytosis
- Key points
- Introduction
- Mastocytosis phenotypes
- Disease burden from a patient perspective
- How to assess symptom severity and quality of life
- Discussion
- Summary
- Clinics care points
- Conflicts of interest
- Effect of Gender and Special Considerations for Women in Mastocytosis and Anaphylaxis
- Key points
- Introduction
- Anaphylaxis
- Mastocytosis
- Clinics care points
- Disclosure
- Update on Mast Cell Proteases as Drug Targets
- Key points
- Introduction
- Tryptases: abundance, multiplicity, and genetic variation
- Pharmacologic inactivation of β-tryptases
- Chymase
- Cathepsin G and dipeptidyl peptidase-I
- Carboxypeptidase A3
- Summary
- Clinics care points
- Disclosures
- No. of pages: 240
- Language: English
- Edition: 1
- Volume: 43-4
- Published: September 28, 2023
- Imprint: Elsevier
- Hardback ISBN: 9780443181832
- eBook ISBN: 9780443181849
CA